-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Colistin methanesulfonate is an inactive prodrug of colistin (also known as polymyxin E), which is an antibiotic with effect against most Gram-negative bacteria, but also causes nephro- and neurotoxicity [1]. Colistin is produced by certain strains of the bacteria Paenibacillus polymyxa, and belongs to the class of polypeptide antibiotics known as polymyxins. In Vitro: Studying the time-kill kinetics of Colistin methanesulfonate against a type culture of pseudomonas aeruginosa found that 8.0 or 32 mg/l Colistin methanesulfonate began killing at approximately 90 or 30 min, and the mean AUC0-240 values were 186.3±6.0 and 90.4±4.1, respectively [2]. Besides, by investigation among mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis, Colistin methanesulfonate was found to require a concentration of 16 times the MIC to achieve complete killing within 24 h [3]. In Vivo: no data available. Clinical trial: no data available.
[1] Nation R L, Li J. Colistin in the 21st century.[J]. Current Opinion in Infectious Diseases, 2009, 22(6): 535-543.
[2] Bergen P J, Li J, Rayner C R, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.[J]. Antimicrobial Agents and Chemotherapy, 2006, 50(6): 1953-1958.
[3] Li J, Turnidge J D, Milne R W, et al. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis[J]. Antimicrobial Agents and Chemotherapy, 2001, 45(3): 781-785.
-
- Properties
-
Overview